Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Anifrolumab (Saphnelo): blocking type I interferon in lupus

A 2-minute narrated animation of type I interferon signaling in SLE and IFNAR1 blockade by anifrolumab (Saphnelo). Open professional education.

Open access · No registration required · English narration · 2:03

A narrated mechanism animation: immune complexes, type I interferon signaling and IFNAR1 blockade.

Where anifrolumab interrupts the signal

In systemic lupus erythematosus (SLE), type I interferons can sustain a cycle of immune activation. The animation follows immune-complex sensing, interferon release and signaling through IFNAR1/IFNAR2, JAK1/TYK2 and STAT proteins to interferon-stimulated genes.

Anifrolumab (Saphnelo) binds IFNAR1, a subunit of the type I interferon receptor, and inhibits this signaling pathway. Its target is the receptor; it does not directly inhibit JAK or TYK2 enzymes. The simplified sequence helps locate the intervention within the immune network, while individual clinical responses vary.

Anifrolumab is used with standard therapy for adults with moderate-to-severe SLE. Current U.S. labeling does not recommend its use in severe active lupus nephritis or severe active CNS lupus. This mechanism overview is not a treatment-selection or dosing guide.

Connect the mechanisms

Scientific context: type I interferon blockade · current U.S. prescribing information. Reviewed October 3, 2026.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: AnifrolumabAutoimmune diseaseHow treatment worksLupusMechanism of actionMedical educationSLETreatmentTYK2Type I interferon